Summary of SenesTech (SNES) Conference Call - August 19, 2025 Company Overview - **Company**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Biotech and Life Sciences, specifically pest control - **Core Product**: Rodent birth control solutions disrupting the rodenticide market, focusing on sustainable pest management [3][4] Key Points and Arguments Industry Context - **Rodent Problem**: Rodents cause over $27 billion in infrastructure damage annually in the U.S. and destroy nearly 20% of the world's food supply [4][5] - **Current Solutions**: Existing rodenticides are largely poisons that are ineffective and harmful, leading to resistance and bans in various jurisdictions [6][7] Product Differentiation - **Unique Approach**: SenesTech focuses on suppressing rodent reproduction rather than increasing mortality rates, with products that are humane and do not harm non-target species [11][12] - **Evolve Product**: Launched as a solid bait, it has an 18-month shelf life and is designed for both professional and DIY use, significantly expanding market reach [16][17] Market Position and Competitive Advantage - **Regulatory Head Start**: SenesTech has a FIFRA 25B minimum risk exemption and approvals in 48 states, giving it a significant advantage over competitors [18][19] - **Intellectual Property**: The company holds patents and trade secrets that protect its unique formulations and efficacy studies [20][21] Market Opportunities - **Market Size**: The U.S. rodenticide market is approximately $1 billion, with a global market of $4.5 billion [26][63] - **Target Verticals**: Key markets include consumers, cities and governments, pest management, agribusiness, facilities management, and food production [26][27] Sales and Distribution Strategy - **E-commerce Growth**: E-commerce accounts for over 60% of revenue, with a 78% increase year-over-year, driven by the popularity of Evolve [31][32] - **Municipal Deployments**: Significant traction in cities like Chicago and New York, with successful pilot programs leading to reorders and increased consumer adoption [36][38] Financial Performance - **Revenue Growth**: Total revenue is approximately $2 million annually, with Evolve sales increasing by 94%, making up 83% of second-quarter sales [51][52] - **Gross Margins**: Improved to 65.4% in Q2, driven by the profitability of the Evolve product [55] - **Cash Position**: The company ended the quarter with $6.1 million in cash, with a pro forma cash position of about $12 million, providing a runway into 2027 [60][61] Future Outlook - **Regulatory Tailwinds**: Increasing bans on traditional rodenticides and a push for humane alternatives create a favorable environment for SenesTech's products [63][64] - **Growth Strategy**: Focus on e-commerce, international markets, and government sales, with expectations for strong revenue growth and margin expansion [66][67] Additional Important Points - **International Expansion**: Successful pilot programs in markets like Hong Kong and the Netherlands, with potential for significant orders [43][44] - **Brick and Mortar Retail**: Recent agreements with distributors to expand into physical retail, with a nearly 500% increase in brick-and-mortar sales sequentially [46][47] This summary encapsulates the key insights from the SenesTech conference call, highlighting the company's innovative approach to pest control, market opportunities, and financial performance.

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $625,000, representing a 36% increase year-over-year and a 29% sequential increase [19] - EVOLVE sales increased by 94% year-over-year and accounted for 83% of total revenue, while ContraPest sales decreased by approximately 45% [19] - Gross profit margins improved to 65.4%, up from 54.2% in the same quarter last year and 64.5% sequentially [22] Business Line Data and Key Metrics Changes - EVOLVE now constitutes 83% of total quarterly revenue, with gross profit dollars up 64% compared to last year's Q2 [6][22] - E-commerce sales grew by 78% year-over-year and accounted for over 50% of quarterly sales, with Amazon leading the channel [8][20] - Municipal sales saw a 538% increase year-over-year, driven by deployments in cities like Chicago and New York [21] Market Data and Key Metrics Changes - E-commerce sales were up 78% compared to last year and up 18% sequentially, with significant growth in brick-and-mortar retail sales, which increased nearly 500% sequentially [8][21] - International sales included a follow-on order from the Caribbean, with ongoing regulatory approvals in Australia and New Zealand [12][21] Company Strategy and Development Direction - The company is focused on expanding its market presence through the EVOLVE product line, which has opened new verticals and distribution channels [5][16] - Plans are in place to accelerate e-commerce growth and expand into agricultural applications, where significant opportunities exist [32][14] - The company aims to achieve cash flow breakeven at approximately $1,500,000 in quarterly revenue, with expectations for growth in 2026 [25][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth from city and government trials, anticipating increased orders as results from trials prove successful [33] - The company is optimistic about its position in the market, citing a large addressable global market and regulatory tailwinds [28] - Management highlighted the importance of focusing on the EVOLVE product line to maximize market penetration and operational efficiency [49] Other Important Information - The company ended the quarter with $6,100,000 in cash, following successful financing activities [26] - The new manufacturing facility has the capacity to produce approximately $10,000,000 in revenue, with plans for further expansion [34] Q&A Session Summary Question: Should we expect incremental improvements to gross margins in the coming quarters? - Yes, management expects margins to remain consistent and possibly improve [30] Question: Is there room to accelerate e-commerce growth with additional digital marketing spend? - Yes, plans are in place to accelerate growth across all channels [31] Question: Should we expect higher volumes from cities where the product has been launched? - Yes, as trials prove successful, increased orders and revenues are anticipated [33] Question: What is the potential capacity in terms of dollars of the expanded manufacturing facility? - The facility can produce roughly $10,000,000 in revenue with current operations [34] Question: Are you planning to do more capital raises in the future? - No further financings are anticipated in the near future, as the company has sufficient cash to reach cash flow profitability [36] Question: Would a full-scale New York City expansion require a big capital investment? - No significant capital investment is required immediately, but future expansions may need some capital [38] Question: Do you need to hire additional people to meet growth expectations? - Yes, the company is hiring salespeople and expanding its field team to support growth [40] Question: Are there any active trials that have not been announced? - Yes, there are ongoing trials that have not yet been disclosed [42] Question: How long before you are in store with Tractor Supply? - The company hopes to have news on this in the coming months [46] Question: Can you specify how OpEx will be cut? - Cuts have already been made, and there are no specific plans for further reductions at this time [47]

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]

Company Participation - SenesTech, Inc. will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 3:30 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will engage in virtual one-on-one meetings throughout the event, with arrangements available through Lytham Partners [3] Company Overview - SenesTech is focused on improving global health by managing animal pest populations through fertility control solutions [4] - The company developed ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, along with Evolve and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [4] - SenesTech aims to integrate its products into pest management programs to enhance effectiveness and promote humane, safe, and sustainable pest control [4]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $485,000, an increase of 17% from Q1 2024 [17] - EVOLVE revenue grew by 40% and accounted for 79% of total sales, while ContraPest revenue decreased by approximately 40% [17] - Gross margins increased to 64.5% compared to 32.5% in Q1 2024, with gross profit rising by 132% to $313,000 [20][21] Business Line Data and Key Metrics Changes - EVOLVE product line significantly contributed to revenue growth, with e-commerce sales increasing by 107% [10][18] - Municipal sales saw a sevenfold increase compared to the previous year, driven by new deployments in major cities [19] - ContraPest, while deemphasized, still retains a loyal customer base and is expected to continue generating revenue [17] Market Data and Key Metrics Changes - E-commerce accounted for 61% of overall Q1 sales, with Amazon being the predominant channel [18] - International sales were not recognized in Q1 but are anticipated to grow with pending regulatory approvals in various markets [19][12] Company Strategy and Development Direction - The company is focusing on expanding the EVOLVE product line and enhancing operational efficiencies to achieve profitability [15][25] - Strategic initiatives have been implemented to reduce expenses by $2 million annually, which should improve financial performance in upcoming quarters [15][22] - The company aims to penetrate various markets, including agriculture, zoos, and residential applications, to drive future growth [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for significant growth in municipal applications and other markets [26] - The company is on a pathway to profitability, with a reduced revenue threshold for cash flow breakeven set at $1.5 million quarterly [16][22] - There is a clear focus on executing strategies effectively while maintaining efficiency [25] Other Important Information - The company completed a strategic financing during Q1, raising $1 million and issuing $4 million in short-term warrants [23] - The new larger facility in Phoenix is expected to support increasing demand without significantly raising costs [21] Q&A Session Summary - No questions were asked during the Q&A session, leading to a conclusion of the call [29]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $485,000, an increase of 17% from Q1 2024 [17] - EVOLVE revenue grew by 40% and accounted for 79% of total sales, while ContraPest revenue decreased by approximately 40% [17] - Gross margins increased to 64.5% compared to 32.5% in Q1 2024, with gross profit rising by 132% to $313,000 [20][21] Business Line Data and Key Metrics Changes - EVOLVE product line is driving growth, with significant revenue contributions from e-commerce, which accounted for 61% of total sales and increased by 107% year-over-year [18] - Municipal sales saw a sevenfold increase compared to the previous year, driven by new deployments in major cities [19] - ContraPest continues to have loyal customers, but its sales are being deemphasized as the company focuses on EVOLVE [17] Market Data and Key Metrics Changes - E-commerce sales have expanded to platforms like Amazon, Walmart, and Tractor Supply, contributing significantly to revenue growth [10] - International operations are expected to grow, with agreements signed in 12 countries, including Indonesia and the Philippines [12] - No international sales were recognized in Q1, but potential significant orders are pending regulatory approval [19] Company Strategy and Development Direction - The company is focusing on expanding the EVOLVE product line and improving operational efficiencies to achieve profitability [15][25] - Strategic initiatives have been implemented to reduce expenses by $2 million annually, which will help lower the revenue threshold for cash flow breakeven to $1.5 million quarterly [15][22] - The company aims to revolutionize pest control, particularly in municipal applications, agriculture, and commercial sectors [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in municipal deployments and e-commerce, anticipating continued success in these areas [10][11] - The company is focused on executing its strategy effectively to capitalize on market opportunities and achieve profitability [25][28] - Management highlighted the importance of operational optimization and the potential for significant revenue growth from new markets [25][26] Other Important Information - The company completed a strategic financing that raised $1 million and included short-term warrants, providing additional capital without significant dilution [23] - The company has moved into a larger facility to meet increasing demand without dramatically increasing costs [21] Q&A Session Summary - No questions were asked during the Q&A session, and the call concluded without further inquiries [29]

Core Insights - SenesTech, Inc. reported a 17% increase in revenues for Q1 2025, reaching $485,000 compared to $415,000 in Q1 2024, with Evolve product sales growing 40% year-over-year, now accounting for 79% of total revenue [8][3] - The company achieved a record gross profit margin of 64.5%, up from 32.5% in the same quarter last year [8] - The net loss for Q1 2025 was $1.7 million, slightly improved from a loss of $1.8 million in Q1 2024, while adjusted EBITDA loss improved to $1.5 million from $1.7 million [8] Operational and Strategic Highlights - The Evolve™ Rat and Evolve™ Mouse products are now the largest revenue drivers for SenesTech, reflecting a successful product expansion strategy [3] - E-commerce revenue more than doubled year-over-year, with a 107% increase attributed to improved platform functionality and digital marketing efforts [4] - The company has expanded Evolve deployments in major U.S. municipalities, with positive early adoption in Chicago and a pilot program in New York City [5] International Growth - SenesTech has signed distribution agreements in eleven countries and territories, with product shipments already initiated in The Netherlands, Hong Kong, the UAE, and the Maldives [6] - Regulatory approvals are pending in Australia and New Zealand, with additional launches planned for later in 2025 [6] Financial Performance - The company reported a gross profit of $313,000 for Q1 2025, compared to $135,000 in Q1 2024, indicating improved operational efficiency [17] - Total current assets increased to $3.164 million as of March 31, 2025, up from $2.813 million at the end of 2024 [16] - The company has lowered its breakeven revenue threshold from $12 million to approximately $7 million, indicating a path toward positive cash flow [6]

Company Overview - SenesTech, Inc. is a leader in fertility control for managing animal pest populations, having developed products like ContraPest and Evolve, which are designed to be humane, effective, and sustainable [5]. - The company has entered into an exclusive distribution agreement with Asa Jaya Mandiri LTD (AJM) for the commercialization of Evolve™ in Indonesia, marking its eleventh international distribution agreement [1][4]. Industry Context - Rats are a significant threat to palm oil plantations in Indonesia, causing estimated yield reductions of 5-10% annually, which translates to potential economic losses of USD 540 million to USD 1.08 billion each year, given the palm oil market's value of approximately USD 10.8 billion in 2024 [2]. - The rapid reproduction and adaptability of rats to traditional control methods make long-term population management challenging, highlighting the need for effective fertility control solutions [3]. AJM Profile - Asa Jaya Mandiri LTD (AJM) is a prominent Indonesian trading company with a specialized pest management operation, committed to high quality and standards in its offerings [4][7]. - AJM has over a decade of experience and a diverse portfolio of products sourced globally, enabling it to cater to the unique needs of its customers [7].

Financial Results Announcement - SenesTech, Inc. will report its first quarter 2025 financial results after market close on May 8, 2025 [1] - A conference call is scheduled for the same day at 5:00 p.m. Eastern time to review the results [1] Conference Call Details - Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407 [2] - A live webcast of the conference call will be available on the Company's website [2] Replay Information - A teleconference replay will be available for seven days after the call [3] - A webcast replay will be accessible for 90 days on the Company's website [3] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control [4] - The company has developed ContraPest, the only U.S. EPA-registered contraceptive for rats, and other minimum risk contraceptives for rodents [4] - The mission is to provide proactive, safe, and sustainable pest management solutions [4]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue increase of 70%, reaching $501,000 for Q4 2024, and a 56% increase in annual revenue to $1.9 million [27][8] - Gross profit margins improved to 61% in Q4 2024, up from 44% in the same quarter last year, with gross profit dollars increasing by 136% [31][8] - The adjusted EBITDA loss was the smallest in company history, with cash burn expected to decrease from $1.5 million to $1 million per quarter [9][34] Business Line Data and Key Metrics Changes - Evolve Rat accounted for 52% of Q4 sales, with a 365% increase compared to the same quarter last year, while Evolve Mouse represented 24% of sales [27][28] - ContraPest sales decreased by 51% as customers transitioned to Evolve solutions [28] Market Data and Key Metrics Changes - E-commerce sales surged by 206% in Q4 2024, representing 55% of total revenue for the quarter [28][29] - The company expanded its distribution agreements in 10 countries, with significant orders from cities like New York and Baltimore [19][15] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven at an annual revenue threshold of $7 million, down from $12 million historically [9] - Strategic financing completed is expected to accelerate progress towards profitability [10][24] - Focus on expanding into municipal markets, warehousing, and international distribution as key growth drivers [22][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting the successful launch of Evolve products and the potential for growth in various markets [11][37] - The company is committed to a focused strategy that emphasizes cost efficiencies and sustainable long-term success [36] Other Important Information - The company is implementing new initiatives to reduce cash burn by $2 million annually and has secured a larger facility to meet increasing demand [9][32] - The introduction of the Lure bait dispenser is expected to enhance product accessibility, although it is not projected to be a high revenue item [53][54] Q&A Session Summary Question: Visibility on New York pilot program - Management indicated that the pilot program in New York will start in April, with potential for expansion based on initial success [42][44] Question: Sales efforts in warehousing and distribution - The company is seeing increased orders from warehousing facilities, particularly in food production, where traditional poisons are not feasible [46][47] Question: E-commerce sales strategy - Management confirmed that advertising and search engine optimization efforts are in place to drive e-commerce sales, with significant growth noted on platforms like Amazon [48][49] Question: Clarification on cash burn reduction - The reduction from $1.5 million to $1 million was clarified as a decrease in cash burn or adjusted EBITDA [50][52] Question: Contribution of Lure bait dispenser - The Lure bait dispenser is seen as a valuable accessory that allows for product use in hard-to-reach areas, generating interest and orders [53][54] Question: Revenue growth from recent contracts - Management noted that regulatory approvals and field trials are necessary before significant revenue contributions can be expected from new contracts [62][64] Question: Traction with big box retailers - The company has seen significant interest from retailers like Ace Hardware, with plans to expand into their warehouses [68][69] Question: Marketing plans for increasing awareness - A comprehensive marketing plan is in place to promote the product's success in municipalities and through social media [71][73] Question: Manufacturing capacity and cost savings - The company has built its supply chain to handle increased demand without constraints, with ongoing efforts to improve manufacturing efficiencies [77][79]